Skip Navigation

Profile

Perry Shen, M.D.Wake Forest Baptist Health

Doctor Rating

4.7 out of 5

206 Ratings
24 Comments
 

Perry Shen, M.D.

Program Director, Surgical Sciences-Oncology
Professor, General Surgery

Clinical Interests

Sarcoma, Hepatobiliary Surgery, Minimally Invasive Liver and Pancreatic Resection, Gastrointestinal Oncology Surgery, Peritoneal Surface Malignancies, Pancreatic Surgery, Melanoma

Contact Information

Returning Patient Appointments: 336-716-4276
Department: 336-716-0545

Email: pshen@wakehealth.edu

Insurance Accepted »

Media Medical Expert »

Education & Training

  • B.A., University of California-Irvine, 1988
  • B.S., University of California-Irvine, 1988
  • M.D., University of Southern California Sch of Medicine, 1992
  • Internship, Obstetrics & Gynecology, J Hopkins-Balti Cty Hosps, 1993
  • Residency, Surgery, U Southern Calif Affil Hosps, 1998
  • Fellowship, John Wayne Cancer Institute, 2000

Board Certifications

  • American Board of Surgery, Surgery

Memberships

  • Am Assn Of Cancer Research
  • North Carolina Medical Assn
  • North Carolina Surgical Assn
  • Soc for Sur Of Alimentary Trac
  • Soc Of Surgical Oncology
  • Southeastern Surgical Congress
  • Southern Surgical Society
  • Society of Graduate Surgeons
  • Am Hepato-Pancreato-Biliary
  • Am Coll Of Surgeons
  • Am Medical Assn
  • Am Soc of Clinical Oncology
  • Assn Of Academic Surgery
  • Forsyth-Davie-Stokes Medical S

NPI Number

  • 1417932575
Perry Shen, M.D.

Doctor Rating

4.7 out of 5

206 Ratings
24 Comments
 

Perry Shen, M.D.

Program Director, Surgical Sciences-Oncology
Professor, General Surgery

Research Interests

Peritoneal Neoplasms; Hyperthermia, Induced; Liver Neoplasms; Colorectal Neoplasms; Chemotherapy, Cancer, Regional Perfusion
More »

Contact Information

Academic: 336-716-0545 | Department: 336-716-0545

Email: pshen@wakehealth.edu

Media Medical Expert »

Recent Publications

Transplantation versus resection for hilar cholangiocarcinoma: an argument for shifting treatment paradigms for resectable disease. Ethun CG, Lopez-Aguiar AG, Anderson DJ, Adams AB, Fields RC, Doyle MB, Chapman WC, Krasnick BA, Weber SM, Mezrich JD, Salem A, Pawlik TM, Poultsides G, Tran TB, Idrees K, Isom CA, Martin RCG, Scoggins CR, Shen P, Mogal HD, Schmidt C,.. Ann Surg. 2018;267(5):797-805.

Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US Extrahepatic Biliary Malignancy Consortium. Schimizzi GV, Jin LX, Davidson JT IV, Krasnick BA, Ethun CG, Pawlik TM, Poultsides G, Tran T, Idrees K, Isom CA, Weber SM, Salem A, Hawkins WG, Strasberg SM, Doyle MB, Chapman WC, Martin RCG, Scoggins C, Shen P, Mogal HD, Schmidt C,.. HPB (Oxford). 2018;20(4):332-339.

Is cytoreductive surgery with hyperthermic intraperitoneal chemotherapy justified for biphasic variants of peritoneal mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International registry. Votanopoulos KI, Sugarbaker P, Deraco M, Morris D, Glehen O, Elias D, De Simone M, Robella M, Heyd B, Kusamura S, Baratti D, Chouliaras K, Russell G, Shen P, Levine EA.. Ann Surg Oncol. 2018;25(3):667-673.

The impact of caudate lobe resection on margin status and outcomes in patients with hilar cholangiocarcinoma: a multi-institutional analysis from the US Extrahepatic Biliary Malignancy Consortium. Bhutiani N, Scoggins CR, McMasters KM, Ethun CG, Poultsides GA, Pawlik TM, Weber SM, Schmidt CR, Fields RC, Idrees K, Hatzaras I, Shen P, Maithel SK, Martin RCG II.. Surgery. 2018;163(4):726-731.

Adjuvant therapy is associated with improved survival after curative resection for hilar cholangiocarcinoma: a multi-institution analysis from the U.S. Extrahepatic Biliary Malignancy Consortium. Krasnick BA, Jin LX, Davidson JT IV, Sanford DE, Ethun CG, Pawlik TM, Poultsides GA, Tran T, Idrees K, Hawkins WG, Chapman WC, Doyle MBM, Weber SM, Strasberg SM, Salem A, Martin RCG, Isom CA, Scoggins C, Schmidt CR, Shen P, Beal E,.. J Surg Oncol. 2018;117(3):363-371.

A multicenter randomized trial to evaluate hematologic toxicities after hyperthermic intraperitoneal chemotherapy with oxaliplatin or mitomycin in patients with appendiceal tumors. Levine EA, Votanopoulos KI, Shen P, Russell G, Fenstermaker J, Mansfield P, Bartlett D, Stewart JH.. J Am Coll Surg. 2018;226(4):434-443.

PCI is not predictive of survival after complete CRS/HIPEC in peritoneal dissemination from high-grade appendiceal primaries. Votanopoulos KI, Bartlett D, Moran B, Haroon CM, Russell G, Pingpank JF, Ramalingam L, Kandiah C, Chouliaras K, Shen P, Levine EA.. Ann Surg Oncol. 2018;25(3):674-678.

Techniques for cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Dodson RM, Kuncewitch M, Votanopoulos KI, Shen P, Levine EA.. Ann Surg Oncol. 2018;():.

Defining early recurrence of hilar cholangiocarcinoma after curative-intent surgery: a multi-institutional study from the US Extrahepatic Biliary Malignancy Consortium. Zhang XF, Beal EW, Chakedis J, Chen Q, Lv Y, Ethun CG, Salem A, Weber SM, Tran T, Poultsides G, Son AY, Hatzaras I, Jin L, Fields RC, Buettner S, Scoggins C, Martin RCG, Isom CA, Idrees K, Mogal HD, Shen P, Maithel SK, Schmidt CR, Pawlik TM.. World J Surg. 2018;():.

The impact of intraoperative re-resection of a positive bile duct margin on clinical outcomes for hilar cholangiocarcinoma. Zhang XF, Squires MH III, Bagante F, Ethun CG, Salem A, Weber SM, Tran T, Poultsides G, Son AY, Hatzaras I, Jin L, Fields RC, Weiss M, Scoggins C, Martin RCG, Isom CA, Idrees K, Mogal HD, Shen P, Maithel SK, Schmidt CR, Pawlik TM.. Ann Surg Oncol. 2018;25(5):1140-1149.

The effect of regional anesthesia on oncologic outcomes after resection of colorectal hepatic metastases. Garland M, Addis D, Russell G, Clark C, Levine E, Howerton R, Votanopoulos K, Dobson S, Shen P.. Am Surg. 2018;84(1):E29-E32.

Defining the chance of statistical cure among patients with extrahepatic biliary tract cancer. Spolverato G, Bagante F, Ethun CG, Poultsides G, Tran T, Idrees K, Isom CA, Fields RC, Krasnick B, Winslow E, Cho C, Martin RC, Scoggins CR, Shen P, Mogal HD, Schmidt C, Beal E, Hatzaras I, Shenoy R, Maithel SK, Pawlik TM.. World J Surg. 2017;41(1):224-231.

Association of optimal time interval to re-resection for incidental gallbladder cancer with overall survival: a multi-institution analysis from the US Extrahepatic Biliary Malignancy Consortium. Ethun CG, Postlewait LM, Le N, Pawlik TM, Buettner S, Poultsides G, Tran T, Idrees K, Isom CA, Fields RC, Jin LX, Weber SM, Salem A, Martin RC, Scoggins C, Shen P, Mogal HD, Schmidt C, Beal E, Hatzaras I, Shenoy R, Kooby DA, Maithel SK.. JAMA Surg. 2017;152(2):143-149.

A novel pathology-based preoperative risk score to predict locoregional residual and distant disease and survival for incidental gallbladder cancer: a 10-institution study from the U.S. Extrahepatic Biliary Malignancy Consortium. Ethun CG, Postlewait LM, Le N, Pawlik TM, Buettner S, Poultsides G, Tran T, Idrees K, Isom CA, Fields RC, Jin L, Weber SM, Salem A, Martin RC, Scoggins C, Shen P, Mogal HD, Schmidt C, Beal E, Hatzaras I, Shenoy R, Merchant N, Cardona K, Maithel SK.. Ann Surg Oncol. 2017;24(5):1343-1350.

Prognostic factors and significance of gastrointestinal leak after cytoreductive surgery (CRS) with heated intraperitoneal chemotherapy (HIPEC). Chouliaras K, Levine EA, Fino N, Shen P, Votanopoulos KI.. Ann Surg Oncol. 2017;24(4):890-897.

Distal cholangiocarcinoma and pancreas adenocarcinoma: are they really the same disease? A 13-institution study from the US Extrahepatic Biliary Malignancy Consortium and the Central Pancreas Consortium. Ethun CG, Lopez-Aguiar AG, Pawlik T, Poultsides G, Idrees K, Fields R, Weber S, Cho C, Martin R, Scoggins C, Shen P, Schmidt C, Hatzaras I, Bentrem D, Ahmad S, Abbott D, Kim HJ, Merchant N, Staley CA, Kooby DA, Maithel SK.. J Am Coll Surg. 2017;224(4):406-413.

Modified frailty index predicts morbidity and mortality after pancreaticoduodenectomy. Mogal H, Vermilion SA, Dodson R, Hsu FC, Howerton R, Shen P, Clark CJ.. Ann Surg Oncol. 2017;24(6):1714-1721.

Phase II randomized trial of negative pressure wound therapy to decrease surgical site infection in patients undergoing laparotomy for gastrointestinal, pancreatic, and peritoneal surface malignancies. Shen P, Blackham A, Lewis S, Clark C, Howerton R, Mogal H, Dodson R, Russell GB, Levine EA.. J Am Coll Surg. 2017;224(4):726-737.

Use of unsolicited patient observations to identify surgeons with increased risk for postoperative complications. Cooper WO, Guillamondegui O, Hines OJ, Hultman CS, Kelz RR, Shen P, Spain DA, Sweeney JF, Moore IN, Hopkins J, Horowitz IR, Howerton RM, Meredith JW, Spell NO, Sullivan P, Domenico HJ, Pichert JW, Catron TF, Webb LE, Dmochowski RR,.. JAMA Surg. 2017;152(6):522-529.

Routine port-site excision in incidentally discovered gallbladder cancer is not associated with improved survival: a multi-institution analysis from the US Extrahepatic Biliary Malignancy Consortium. Ethun CG, Postlewait LM, Le N, Pawlik TM, Poultsides G, Tran T, Idrees K, Isom CA, Fields RC, Krasnick BA, Weber SM, Salem A, Martin RC, Scoggins CR, Shen P, Mogal HD, Schmidt C, Beal E, Hatzaras I, Shenoy R, Cardona K, Maithel SK.. J Surg Oncol. 2017;115(7):805-811.

Effect of epidural compared to patient-controlled intravenous analgesia on outcomes for patients undergoing liver resection for neoplastic disease. Allen S, DeRoche A, Adams L, Slocum KV, Clark CJ, Fino NF, Shen P.. J Surg Oncol. 2017;115(4):402-406.

Gallbladder cancer presenting with jaundice: uniformly fatal or still potentially curable?. Tran TB, Norton JA, Ethun CG, Pawlik TM, Buettner S, Schmidt C, Beal EW, Hawkins WG, Fields RC, Krasnick BA, Weber SM, Salem A, Martin RCG, Scoggins CR, Shen P, Mogal HD, Idrees K, Isom CA, Hatzaras I, Shenoy R, Maithel SK, Poultsides GA.. J Gastrointest Surg. 2017;21(8):1245-1253.

Modified frailty index predicts postoperative outcomes in older gastrointestinal cancer patients. Vermillion SA, Hsu FC, Dorrell RD, Shen P, Clark CJ.. J Surg Oncol. 2017;115(8):997-1003.

Survival after resection of perihilar cholangiocarcinoma in patients with lymph node metastases. Buettner S, van Vugt JLA, Gaspersz MP, Coelen RJS, Roos E, Labeur TA, Margonis GA, Ethun CG, Maithel SK, Poultsides G, Tran T, Idrees K, Isom CA, Fields RC, Krasnick BA, Weber SM, Salem A, Martin RCG, Scoggins CR, Shen P, Mogal HD, Schmidt C,.. HPB (Oxford). 2017;19(8):735-740.

Interval between cytoreductions as a marker of tumor biology in selecting patients for repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Konstantinidis IT, Levine EA, Chouliaras K, Russell G, Shen P, Votanopoulos KI.. J Surg Oncol. 2017;116(6):741-745.

Pathologic and prognostic implications of incidental versus nonincidental gallbladder cancer: a 10-institution study from the United States Extrahepatic Biliary Malignancy Consortium. Ethun CG, Le N, Lopez-Aguiar AG, Pawlik TM, Poultsides G, Tran T, Idrees K, Isom CA, Fields RC, Krasnick BA, Weber SM, Salem A, Martin RCG, Scoggins CR, Shen P, Mogal HD, Schmidt C, Beal E, Hatzaras I, Shenoy R, Russell MC, Maithel SK.. Am Surg. 2017;83(7):679-686.

Evaluating the American College of Surgeons National Surgical Quality Improvement project risk calculator: results from the U.S. Extrahepatic Biliary Malignancy Consortium. Beal EW, Lyon E, Kearney J, Wei L, Ethun CG, Black SM, Dillhoff M, Salem A, Weber SM, Tran TB, Poultsides G, Shenoy R, Hatzaras I, Krasnick B, Fields RC, Buttner S, Scoggins CR, Martin RCG, Isom CA, Idrees K, Mogal HD, Shen P, Maithel SK,.. HPB (Oxford). 2017;19(12):1104-1111.

Surgical site infection is associated with tumor recurrence in patients with extrahepatic biliary malignancies. Buettner S, Ethun CG, Poultsides G, Tran T, Idrees K, Isom CA, Weiss M, Fields RC, Krasnick B, Weber SM, Salem A, Martin RCG, Scoggins CR, Shen P, Mogal HD, Schmidt C, Beal E, Hatzaras I, Shenoy R, Koerkamp BG, Maithel SK, Pawlik TM.. J Gastrointest Surg. 2017;21(11):1813-1820.

Optimal modified frailty index cutoff in older gastrointestinal cancer patients. Garland M, Hsu FC, Shen P, Clark CJ.. Am Surg. 2017;83(8):860-865.

The effects of travel burden on outcomes after resection of extrahepatic biliary malignancies: results from the US Extrahepatic Biliary Consortium. O'Connor SC, Mogal H, Russell G, Ethun C, Fields RC, Jin L, Hatzaras I, Vitiello G, Idrees K, Isom CA, Martin R, Scoggins C, Pawlik TM, Schmidt C, Poultsides G, Tran TB, Weber S, Salem A, Maithel S, Shen P.. J Gastrointest Surg. 2017;21(12):2016-2024.

Outcomes of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients older than 70 years; survival benefit at considerable morbidity and mortality [reply to letter]. Votanopoulos KI, Shen P, Stewart JH, Levine EA, Russell G.. Ann Surg Oncol. 2017;24(Suppl 3):602.

Oncologic effects of preoperative biliary drainage in resectable hilar cholangiocarcinoma: percutaneous biliary drainage has no adverse effects on survival. Zhang XF, Beal EW, Merath K, Ethun CG, Salem A, Weber SM, Tran T, Poultsides G, Son AY, Hatzaras I, Jin L, Fields RC, Weiss M, Scoggins C, Martin RCG, Isom CA, Idrees K, Mogal HD, Shen P, Maithel SK, Schmidt CR, Pawlik TM.. J Surg Oncol. 2017;():.

Stoma creation and reversal after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Doud AN, Levine EA, Fino NF, Stewart JH, Shen P, Votanopoulos KI.. Ann Surg Oncol. 2016;23(2):503-510.

Conditional survival after cytoreductive surgery with heated intraperitoneal chemotherapy for low- and high-grade appendiceal primaries. Mogal HD, Levine EA, Russell G, Shen P, Stewart JH, Votanopoulos KI.. Ann Surg Oncol. 2016;23(2):534-538.

Routine admission to intensive care unit after cytoreductive surgery and heated intraperitoneal chemotherapy: not always a requirement. Mogal HD, Levine EA, Fino NF, Obiora C, Shen P, Stewart JH, Votanopoulos KI.. Ann Surg Oncol. 2016;23(5):1486-1495.

Optimal prognostic lymph node staging system for gallbladder adenocarcinoma: a multi-institutional study [abstract]. Amini N, Kim Y, Wilson A, Georgios GA, Ethun CG, Maithel SK, Poultsides GA, Tran T, Idrees K, Isom CA, Fields RC, Krasnick BA, Weber S, Salem AI, Martin RC, Scoggins C, Shen P, Mogal H, Schmidt CR, Beal EW, Hatzaras I, Shenoy R, Pawlik TM.. Ann Surg Oncol. 2016;23(Suppl 1):S12.

Conditional survival probability of long-term survival after resection of hilar cholangiocarcinoma [abstract]. Buettner S, Margonis G, Kim Y, Ethun CG, Maithel SK, Poultsides GA, Tran T, Idrees K, Isom CA, Fields RC, Krasnick BA, Weber S, Salem AI, Martin RC, Scoggins C, Shen P, Mogal H, Schmidt CR, Beal EW, Hatzaras I, Shenoy R, Pawlik TM.. Ann Surg Oncol. 2016;23(Suppl 1):S107.

A reappraisal of staging laparoscopy in three subtypes of cholangiocarcinoma: a multi-institution analysis from the US Extrahepatic Biliary Malignancy Consortium [abstract]. Davidson JT, Jin L, Krasnick BA, Ethun CG, Pawlik TM, Poultsides GA, Tran TB, Idrees K, Isom CA, Weber S, Salem AI, Hawkins W, Strasberg S, Martin RC, Scoggins C, Shen P, Mogal H, Schmidt CR, Beal EW, Hatzaras I, Shenoy R, Maithel SK, Fields RC.. Ann Surg Oncol. 2016;23(Suppl 1):S9.

A novel pathology-based preoperative risk score to predict distant and locoregional residual disease and survival for incidentally discovered gallbladder cancer: a 10-institution study from the US Extrahepatic Biliary Malignancy Consortium [abstract]. Ethun CG, Postlewait LM, Le N, Pawlik TM, Buettner S, Poultsides GA, Tran T, Idrees K, Isom CA, Fields RC, Jin L, Weber S, Salem AI, Martin RC, Scoggins C, Shen P, Mogal H, Schmidt CR, Beal EW, Hatzaras I, Shenoy R, Cardona K, Maithel SK.. Ann Surg Oncol. 2016;23(Suppl 1):S11.

The optimal time-interval to re-resection for incidentally discovered gallbladder cancer: a multi-institution analysis from the US Extrahepatic Biliary Malignancy Consortium [abstract]. Ethun CG, Postlewait LM, Le N, Pawlik TM, Buettner S, Poultsides GA, Tran T, Idrees K, Isom CA, Fields RC, Jin L, Weber S, Salem AI, Martin RC, Scoggins C, Shen P, Mogal H, Schmidt CR, Beal EW, Hatzaras I, Vitiello G, Kooby DA, Maithel SK.. Ann Surg Oncol. 2016;23(Suppl 1):S104.

The effect of postoperative morbidity on long-term survival after curative resection for extrahepatic biliary tumors: a multi-institution analysis from the US Extrahepatic Biliary Malignancy Consortium [abstract]. Jin L, Krasnick BA, Davidson JT, Ethun CG, Pawlik TM, Poultsides GA, Tran TB, Idrees K, Isom CA, Weber S, Salem AI, Hawkins W, Strasberg S, Martin RC, Scoggins C, Shen P, Mogal H, Schmidt CR, Beal EW, Hatzaras I, Shenoy R, Maithel SK, Fields RC.. Ann Surg Oncol. 2016;23(Suppl 1):S117.

Impact of chemotherapy and external-beam radiation therapy on outcomes among patients with resected gallbladder cancer: a multi-institutional analysis [abstract]. Kim Y, Amini N, Georgios GA, Wilson A, Ethun CG, Poultsides GA, Tran T, Idrees K, Isom CA, Fields RC, Krasnick BA, Weber S, Salem AI, Martin RC, Scoggins C, Shen P, Mogal H, Schmidt CR, Beal EW, Hatzaras I, Shenoy R, Cardona K, Maithel SK, Pawlik TM.. Ann Surg Oncol. 2016;23(Suppl 1):S12.

Curative resection for hilar cholangiocarcinoma: does adjuvant therapy impact overall survival? A multi-institution analysis from the US Extrahepatic Biliary Malignancy Consortium [abstract]. Krasnick BA, Jin L, Davidson JT, Ethun CG, Pawlik TM, Poultsides GA, Tran T, Idrees K, Isom CA, Weber S, Salem AI, Hawkins W, Strasberg S, Martin RC, Scoggins C, Shen P, Mogal H, Schmidt CR, Beal EW, Hatzaras I, Shenoy R, Maithel SK, Fields RC.. Ann Surg Oncol. 2016;23(Suppl 1):S113.

Effect of preoperative bilirubin on outcomes of completely resected hilar cholangiocarcinoma: a multi-institutional analysis [abstract]. Mogal H, Dodson R, Fino N, Ethun CG, Pawlik TM, Poultsides G, Tran T, Idrees K, Isom CA, Fields RC, Jin L, Weber S, Salem AI, Martin RC, Scoggins C, Schmidt CR, Beal EW, Hatzaras I, Shenoy R, Maithel SK, Shen P.. Ann Surg Oncol. 2016;23(Suppl 1):S113.

Rates and patterns of recurrence following complete resection of hilar cholangiocarcinoma: results from the US Extrahepatic Biliary Consortium [abstract]. Mogal H, O'Connor S, Fino N, Ethun CG, Pawlik TM, Poultsides GA, Tran TB, Idrees K, Isom CA, Fields RC, Jin L, Weber S, Salem AI, Martin RC, Scoggins C, Schmidt CR, Beal EW, Hatzaras I, Shenoy R, Maithel SK, Shen P.. Ann Surg Oncol. 2016;23(Suppl 1):S108.

Gallbladder cancer presenting with jaundice: uniformly fatal or still potentially curable? [abstract]. Tran TB, Norton JA, Ethun CG, Pawlik TM, Buettner S, Idrees K, Isom CA, Fields RC, Krasnick BA, Weber S, Salem AI, Martin RC, Scoggins C, Shen P, Mogal H, Schmidt CR, Beal EW, Hatzaras I, Shenoy R, Maithel SK, Poultsides GA.. Ann Surg Oncol. 2016;23(Suppl 1):S116-S117.

Association of survival, postoperative morbidity and mortality following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy using quality of life assessments [abstract]. Dodson RM, Mogal H, Russell G, Duckworth KE, Votanopoulos K, Shen P, Levine EA, McQuellon RP.. Ann Surg Oncol. 2016;23(Suppl 1):S35.

Prognostic molecular subtypes of low-grade cancer of the appendix. Levine EA, Votanopoulos KI, Qasem SA, Philip J, Cummins KA, Chou JW, Ruiz J, D'Agostino R, Shen P, Miller LD.. J Am Coll Surg. 2016;222(4):493-503.

Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: review of indications and outcomes. Mogal H, Chouliaras K, Levine EA, Shen P, Votanopoulos KI.. J Gastrointest Oncol. 2016;7(1):129-142.

Peritoneal dissemination from high-grade appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Cummins KA, Russell GB, Votanopoulos KI, Shen P, Stewart JH, Levine EA.. J Gastrointest Oncol. 2016;7(1):3-9.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Professor, General Surgery

Clinical Interests

Sarcoma, Hepatobiliary Surgery, Minimally Invasive Liver and Pancreatic Resection, Gastrointestinal Oncology Surgery, Peritoneal Surface Malignancies, Pancreatic Surgery, Melanoma
Perry Shen, M.D.

Perry Shen, M.D.

Program Director, Surgical Sciences-Oncology
Professor, General Surgery

Doctor Rating

4.7 out of 5

Perry Shen, M.D.206 Ratings
24 Comments


 

Doctor Ratings

The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Press Ganey Patient Satisfaction Survey

CP concern for questions/worries
4.8
CP efforts to include in decisions
4.7
CP explanations of prob/condition
4.8
CP spoke using clear language
4.8
Friendliness/courtesy of CP
4.9
Likelihood of recommending CP
4.8
Patients' confidence in CP
4.9
Time CP spent with patient
4.6
Wait time at clinic
3.7



Patient Comments

Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.

3/15/2018

Dr Shen is an excellent physician.

3/10/2018

Dr. Shen is wonderful!

3/7/2018

good

2/19/2018

I would drive the 2.5 hours to this hospital for any procedure I need done! Very happy with everything!

2/12/2018

I think the world of Dr Shen.He is a wonderful Dr who is caring and very knowledgeable. He was a God sent blessing for me .

2/2/2018

Dr Shen is always very professional and I have a lot of confidence in him.

2/2/2018

Dr Shen is wonderful! He saved my life. His office is very busy. I know he sees a lot of patients and I think that was the reason for the long wait.

1/1/2018

excellent

12/28/2017

He was wonderful!! I thank GOD for him!!

12/27/2017

it as my first visit with this doctor. I was referred by my oncologist. the initial wait time was long. thereafter things went more quickly. I was very impressed with all staff I had contact with.

12/27/2017

Dr Shen was in the exam room probably 3 minutes. Spent more time talking to his 3rd year med student who was a very nice guy.

12/27/2017

good visit I was shocked at the results therefore wasn't prepared to ask the necessary questions that I would like to have asked.

9/21/2017

*Dr. Shen is excellent with all my concerns and very kind and professional!

9/14/2017

We think Dr. Perry Shen is top-notch.

9/6/2017

Good Dr. Shen always answers any questions I have and never rushes me out. He is a good person.

8/16/2017

*Dr. Shen has done surgery on me twice. He is an excellent surgeon. I wouldn't want anybody else but him.

8/4/2017

I have recommended *Dr. Shen to several people.

7/26/2017

great doctor!!!!

7/24/2017

good

7/6/2017

Excellent in every way. Wouldn't ask for anyone else to treat me.

6/26/2017

Very detailed explanation of my condition and plan of approach for my treatment and tests to be conducted. Very courteous, professional and concern

5/21/2017

Would recommend him for surgery, not follow up.

5/9/2017

Dr. Shen very nice, checked the website on info about him. On the mark.

4/24/2017

I would & have recommended Dr. Perry Shen to friends & family he saved my life Dr. Perry Shen is a GOD sent and i thank GOD everyday for him!!!!

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
Six Wake Forest Baptist Specialties Earn U.S. News RankingsComprehensive Cancer Centers National Designation is Renewed2017-2018 Best DoctorsNursing Magnet StatusJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.

© Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157. All Rights Reserved.